First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 380-390

  Schuler, Martin ^a,b   Wu, Yi Long ^c   Hirsh, Vera ^d   O'Byrne, Kenneth ^e   Yamamoto, Nobuyuki ^f   Mok, Tony ^g   Popat, Sanjay ^h   Sequist, Lecia V ⁱ   Massey, Dan ^j   Zazulina, Victoria ^j   Yang, James C H ^k  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BOEHRINGER INGELHEIM LTD   (United Kingdom)

^k NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Afatinib; Brain metastases; Epidermal growth factor receptor; NSCLC

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PLATINUM COMPLEX; QUINAZOLINE DERIVATIVE;

ADULT; AGED; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED STUDY; ENZYMOLOGY; GENETICS; LUNG TUMOR; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84962521878     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.11.014     Document Type: Conference Paper

References (33)

1. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005; 23: 6207-6219.
2. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007; 12: 884-898.
3. Fan Y, Huang Z, Fang L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther. 2013; 6: 1789-1803.
4. Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015; 10: 156-163.
5. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006; 24: 1295-1304.
6. Ruderman N, Hall R. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer. 1965; 18: 298-306.
7. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-Tumor patients: natural history and results of treatment. Cancer. 1981; 48: 384-394.
8. Hendriks LE, Smit EF, Vosse BA, et al. EGFR mutated nonsmall cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014; 84: 86-91.
9. Bhatt VR, Kedia S, Kessinger A, et al. Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations. J Clin Oncol. 2013; 31: 3162-3164.
10. Ali A, Goffin JR, Arnold A, et al. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol. 2013; 20: e300-e306.
11. Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013; 82: 282-287.
12. Park SJ, Kim HT, Lee DH, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012; 77: 556-560.
13. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation. Eur Respir J. 2011; 37: 624-631.
14. Song Z, Zhang Y. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases. J Clin Neurosci. 2014; 21: 591-595.
15. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann Oncol. 2013; 24: 993-999.
16. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27: 4702-4711.
17. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012; 343: 342-350.
18. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-3334.
19. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-222.
20. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3342-3350.
21. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatinbased chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-151.
22. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol. 2012; 13: 539-548.
23. Campas C, Castaner R, Bolos J. BIBW-2992. Dual EGFR/HER2 inhibitor oncolytic. Drugs Fut. 2008; 33: 649.
24. Yang JC, Sequist LV, Geater SL, et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer. J Thorac Oncol. 2013; 8: S139.
25. European Medicines Agency. Giotrif-Summary of Product Characteristics, Annex 1. 2013. http: //www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002280/WC500152392.pdf. Accessed June 18, 2015.
26. Food and Drug Administration. Afatinib. 2015. http: //www.fda.gov/Drugs/InformationOnDrugs/Approved Drugs/ucm360574.htm. Accessed June 18, 2015.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
28. van VM, Kal HB, Taphoorn MJ, et al. Changes in bloodbrain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep. 2002; 9: 683-688.
29. Dhruva N, Socinski MA. Carcinomatous meningitis in nonsmall-cell lung cancer: response to high-dose erlotinib. J Clin Oncol. 2009; 27: e31-e32.
30. Grommes C, Oxnard GR, Kris MG, et al. "Pulsatile" highdose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011; 13: 1364-1369.
31. Hata A, Kaji R, Fujita S, et al. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol. 2011; 6: 653-654.
32. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006; 24: 4517-4520.
33. Jackman DM, Mach SL, Heng JC, et al. Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol. 2013; 31(suppl 15): 8116.